Survival analysis of hepatocellular carcinoma patients with preoperative transcatheter arterial chemoembolization

doi:10.3877/cma.j.issn.1674-0793.2008.03.010

Abstract

Abstract:

Objective

To evaluate prognosis of HCC patients underwent preoperative transcatheter arterial chemoembolization(TACE).

Methods

Clinic pathologic datum of HCC patients were retrospectively reviewed,which were divided into TACE group(Group A,139 cases)and non-TACE group(Group B,156 cases).The survival rates of two groups were compared.

Results

There were no significant differences between two groups. In patients with disseminated nodules, ductal invasion and poorly differentiated tumor, The survival rates were significantly higher in TACE group than non-TACE group,respectively (P＜0.05).

Conclusion

Preoperative TACE is not suitable for all patients of HCC. The HCC patients with disseminated nodules, ductal invasion and poorly differentiated tumor were more benefit from preoperative TACE.

Key words: Carcinoma,hepatocellular, TACE, Prognosis, Survival analysis

Zhi-qiang LIN, Wu-sheng YU, Zai-guo WANG, Zhen-wei YE, Xia-rong HU, Rong-ping GUO, Wei WEI. Survival analysis of hepatocellular carcinoma patients with preoperative transcatheter arterial chemoembolization[J]. Chinese Archives of General Surgery(Electronic Edition), 2008, 02(03): 209-213.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2008.03.010

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2008/V02/I03/209

Figures/Tables 5

References 12

1	Lai EC,Lau WY.The continuing challenge of hepatic cancer in Asia.Surgeon,2005,3(3):210-215.
2	Lau WY,Ho SK,Yu SC,et al.Salvage Surgery following downstaging of unresectable hepatocellular carcinoma.Ann Surg 2004,240(2):299-305.
3	Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology,2003,37(2):429-442.
4	Sugo H,Futagawa S,Beppu T,et al.Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence.World J Surg,2003,27(12):1295-1299.
5	Rose DM, chapman WC, Brockenbrough AT, et al. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg,1999,177(5):405-410.
6	Adachi E，Matsumata T,Nishizaki T,et al.Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma:the relationship between postoperative course and tumor necrosis.Cancer,1993,72(12):3593-3598.
7	Luo YQ,Wang Y,Chen H,et al.Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int,2002,1(4):523-526.
8	Huang J,He X,Lin X,et al.Effect of preoperative branscatheter arterial chemoembolization on tumor cell activity in hepatocellular.Chin Med J(Engl),2000,113(5):446-448.
9	Sasaki A,Iwashita Y,Shibata K,et al.Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma.Eur J Surg Oncol,2006,32(7):773-779.
10	Ochiai T, Sonoyama T, Hironaka T, et al. Hepatectomy with chemoembolization for treatment of hepatocellular carcinoma. Hepatogastroenterology,2003,50(51):750-755.
11	Kaibori M,Tanigawa N,Matsui Y,et al.Influence of transcatheter arterial chemoembolization on the prognosis after hepatectomy for hepatocellular carcinoma in patients with severe liver dysfunction.Anticancer Res,2006,26(5B):3685-3692.
12	郭荣平,俞武生,韦玮,等.PCNA 在接受过术前经导管肝动脉栓塞化疗的肝癌组织中的表达及其预后意义.癌症,2008,27(2):201-205.

	A组(例%)	B组(例%)	x ²值	P值
性别			1.158	0.276
男	120(86.3%)	141(90.4%)
女	19 (13.7%)	15(9.6%)
年龄（岁）			3.124	0.210
＜40	43(30.9%)	36(23.1%)
40～60	71(51.1%)	82(52.6%)
＞60	25(18.0%)	38(24.4%)
治疗前AFP			0.127	0.722
+	98（70.5%）	107（68.6%）
-	41（29.5%）	49（31.4%）
HBsAg			1.352	0.245
+	124(89.2%)	132(84.6%)
-	15(10.8%)	24(15.4%)
肝功能分级			2.207	0.137
A级	135（97.1%）	155（99.4%）
B级	4（2.9%）	1（0.6%）
癌栓			0.924	0.336
有	36 (25.9%)	33 (21.2%)
无	103(74.1%)	123(78.8%)
肿瘤数目			3.521	0.172
单个	78(56.1%)	104(66.7%)
多发	61(43.9%)	52(33.3%)
肿瘤包膜			0.465	0.792
不完整	86(61.9%)	92(58.9%)
完整	53(38.1%)	64(41.1%)
肿瘤直径			2.058	0.357
≤5cm	47(33.8%)	41(26.3%)
＞5cm	92(66.2%)	115(73.7%)
病理分级			0.529	0.467
Ⅰ～Ⅱ	77(66.4%)	110(70.5%)
Ⅲ～Ⅳ	39(33.6%)	46(29.5%)
手术评估（%）			0.103	0.748
根治性	92（66.2%）	106（67.9%）
姑息性	47（33.8%）	50（32.1%）

	A组(例%)	B组(例%)	x ²值	P值
性别			1.158	0.276
男	120(86.3%)	141(90.4%)
女	19 (13.7%)	15(9.6%)
年龄（岁）			3.124	0.210
＜40	43(30.9%)	36(23.1%)
40～60	71(51.1%)	82(52.6%)
＞60	25(18.0%)	38(24.4%)
治疗前AFP			0.127	0.722
+	98（70.5%）	107（68.6%）
-	41（29.5%）	49（31.4%）
HBsAg			1.352	0.245
+	124(89.2%)	132(84.6%)
-	15(10.8%)	24(15.4%)
肝功能分级			2.207	0.137
A级	135（97.1%）	155（99.4%）
B级	4（2.9%）	1（0.6%）
癌栓			0.924	0.336
有	36 (25.9%)	33 (21.2%)
无	103(74.1%)	123(78.8%)
肿瘤数目			3.521	0.172
单个	78(56.1%)	104(66.7%)
多发	61(43.9%)	52(33.3%)
肿瘤包膜			0.465	0.792
不完整	86(61.9%)	92(58.9%)
完整	53(38.1%)	64(41.1%)
肿瘤直径			2.058	0.357
≤5cm	47(33.8%)	41(26.3%)
＞5cm	92(66.2%)	115(73.7%)
病理分级			0.529	0.467
Ⅰ～Ⅱ	77(66.4%)	110(70.5%)
Ⅲ～Ⅳ	39(33.6%)	46(29.5%)
手术评估（%）			0.103	0.748
根治性	92（66.2%）	106（67.9%）
姑息性	47（33.8%）	50（32.1%）

	A组			B组			x ²值	P值
	1年	3年	5年	1年	3年	5年	x ²值	P值
总生存率	89.1	57.8	46.0	78.7	52.1	38.1	1.862	0.172
播散结节	88.7	43.2	26.9	60.2	31.8	21.5	5.058	0.025
癌栓	80.1	28.3	14.2	36.7	11.0	11.0	7.909	0.005
Ⅲ～Ⅳ级	75.8	34.9	30.0	48.3	20.7	13.8	7.293	0.007

	A组			B组			x ²值	P值
	1年	3年	5年	1年	3年	5年	x ²值	P值
总生存率	89.1	57.8	46.0	78.7	52.1	38.1	1.862	0.172
播散结节	88.7	43.2	26.9	60.2	31.8	21.5	5.058	0.025
癌栓	80.1	28.3	14.2	36.7	11.0	11.0	7.909	0.005
Ⅲ～Ⅳ级	75.8	34.9	30.0	48.3	20.7	13.8	7.293	0.007

[1]	Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[2]	Jie Xu, Yajun Li, Junwei Han. Comparison of the efficacy of radical laparoscopic total gastrectomy in the treatment of overweight gastric cancer with two approaches [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 19-22.
[3]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[4]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[5]	Xiangyu Qu, Yigang Zhang, Haoling Li, Tian Qiu, Yi Tan. Diagnostic and prognostic role of USP24 and its co-expression of tumor metabolic genes in hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 659-662.
[6]	Wen Gu, Shouxin Ling, Haili Tang, Xuemei Gan. Comparison of two different surgical approaches for open radical surgery in patients with papillary thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 687-690.
[7]	Chengwang Fu, Dagang Yang, Rong Wang, Futang Li. Research progress of nutritional and inflammatory markers in resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 704-708.
[8]	Mengjie Liang, Huanhuan Zhu, Xingzhou Wang, Hang Jiang, Shichao Ai, Feng Sun, Peng Song, Meng Wang, Song Liu, Xuefeng Xia, Junfeng Du, Shuang Fu, Xiaofeng Lu, Xiaofei Shen, Wenxian Guan. Analysis of prognosis and postoperative complications of gastric cancer patients undergoing conversion therapy with combined immunotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 619-623.
[9]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[10]	Yu Gong, Yuan Liao, Mei Shang. Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 818-824.
[11]	Xiaoling Guan, Wenying Zhou, Hongping Chen. Predictive value of PTAAR for short-term prognosis of patients with hepatitis B virus-related acuteon-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 841-845.
[12]	Yu Liu, Shaobin Duan, Zhixiang Ding, Zhitao Shi. Expression of miR-34a-5p in colon cancer patients and its correlation with clinical characteristics and prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 485-490.
[13]	Qianqian Chen, Chen Yuan, Ji Liu, Tingting Yin. Effects of multi-slice spiral CT parameters，carcinoembryonic antigen，mismatch repair gene，and pathological indicators on prognosis of colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 507-511.
[14]	Mingfen Zeng, Yan Wang. Study on the correlation between CT and color Doppler ultrasound diagnostic parameters and the condition and prognosis of patients with acute pancreatitis complicated with fatty liver [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 531-535.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Please choose a citation manager

Content to export